Pharmabiz4h
Innovent Biologics, ASK Pharm announce China’s NMPA approval of limertinib to treat metastatic EGFR T790M-mutated NSCLCr
Innovent Biologics, ASK Pharm announce China’s NMPA approval of limertinib to treat metastatic EGFR T790M-mutated NSCLCr: San Francisco Saturday, January 18, 2025, 09:00 Hrs [IS ...
Exxon Mobil and Chevron Megadeals Are Cleared of FTC Antitrust Concerns
Pioneer Natural Resources’ former CEO and Hess’s CEO are prohibited from serving on the oil companies’ boards ...
Innovent Biologics: Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...
Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...
Johnson & Johnson's RYBREVANT Plus Chemotherapy Approved In Canada For Advanced Lung Cancer
Johnson & Johnson (JNJ) announced that Health Canada has issued a Notice of Compliance for RYBREVANT (amivantamab for injection) in ...
Cure Today3d
FDA Grants Priority Review to Sunvozertinib for EGFR Exon20+ NSCLC
The Food and Drug Administration has accepted and granted priority review to a new drug application for sunvozertinib.
Oric Pharmaceuticals announces clinical supply agreement with Janssen
ORIC Pharmaceuticals (ORIC) announced that the company has entered into a supply agreement with Janssen Research & ...
PharmiWeb3d
HUTCHMED Announces NMPA Full Approval for ORPATHYS…
Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been granted approval by the China National Medical Products ...
The Pharma Letter3d
NMPA full approval for Orpathys
Chinese biopharma Hutchmed today announced that the supplemental New Drug Application for Orpathys (savolitinib) has been ...
HUTCHMED Announces NMPA Full Approval For ORPATHYS® (Savolitinib) In China For Patients With Locally Advanced Or Metastatic MET Exon 14 NSCLC
Indication expands to include treatment-naïve patients - - The 2021 conditional approval in previously treated patients converted to ful ...
ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones
Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients ...
The Bakersfield Californian4d
ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational ...
Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC ...